Terms: = Germ cell tumor AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
18 results:
1. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
[TBL] [Abstract] [Full Text] [Related]
2. Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines.
Landes JR; Bartley BR; Moore SA; He Q; Simonette R; Rady PL; Doan HQ; Tyring SK
Clin Exp Dermatol; 2023 Jul; 48(8):903-908. PubMed ID: 37191210
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma.
Moore SA; Narayanan D; Simonette RA; Bartley BR; Doan HQ; Rady PL; Tyring SK
Clin Exp Dermatol; 2022 Jul; 47(7):1354-1357. PubMed ID: 35120268
[TBL] [Abstract] [Full Text] [Related]
5. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract] [Full Text] [Related]
6. xpo1/crm1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
[TBL] [Abstract] [Full Text] [Related]
7. Subcellular Distribution of p53 by the p53-Responsive lncRNA
Mitra S; Muralidharan SV; Di Marco M; Juvvuna PK; Kosalai ST; Reischl S; Jachimowicz D; Subhash S; Raimondi I; Kurian L; Huarte M; Kogner P; Fischer M; Johnsen JI; Mondal T; Kanduri C
Cancer Res; 2021 Mar; 81(6):1457-1471. PubMed ID: 33372039
[TBL] [Abstract] [Full Text] [Related]
8. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract] [Full Text] [Related]
9. The sodium pump α1 subunit regulates bufalin sensitivity of human glioblastoma cells through the p53 signaling pathway.
Lan YL; Zou YJ; Lou JC; Xing JS; Wang X; Zou S; Ma BB; Ding Y; Zhang B
Cell Biol Toxicol; 2019 Dec; 35(6):521-539. PubMed ID: 30739221
[TBL] [Abstract] [Full Text] [Related]
10. Dual Inhibition of Bcl-2/Bcl-xL and xpo1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract] [Full Text] [Related]
11. A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group.
Margol AS; Yeo KK; Xia C; Onar A; Robison NJ; Freyer DR; Dhall G
J Neurooncol; 2018 Dec; 140(3):575-582. PubMed ID: 30173409
[TBL] [Abstract] [Full Text] [Related]
12. Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors.
Barazeghi E; Prabhawa S; Norlén O; Hellman P; Stålberg P; Westin G
BMC Cancer; 2018 Jul; 18(1):764. PubMed ID: 30045709
[TBL] [Abstract] [Full Text] [Related]
13. The xpo1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma cells Grown
Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
[TBL] [Abstract] [Full Text] [Related]
14. crm1/xpo1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
[TBL] [Abstract] [Full Text] [Related]
15. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract] [Full Text] [Related]
16. [Clinical symptoms at the diagnosis of the craniopharyngioma].
Rucka E; Wędrychowicz A; Zygmunt-Górska A; Starzyk J
Pediatr Endocrinol Diabetes Metab; 2012; 18(2):58-62. PubMed ID: 22781882
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a functional nuclear export sequence in BRCA1.
Rodríguez JA; Henderson BR
J Biol Chem; 2000 Dec; 275(49):38589-96. PubMed ID: 10991937
[TBL] [Abstract] [Full Text] [Related]
18. A comparison of the activity, sequence specificity, and crm1-dependence of different nuclear export signals.
Henderson BR; Eleftheriou A
Exp Cell Res; 2000 Apr; 256(1):213-24. PubMed ID: 10739668
[TBL] [Abstract] [Full Text] [Related]
